Acute Pancreatitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Diagnosis, By End-User By Region & Competition, 2020-2030F

Description

Global Acute Pancreatitis Market was valued at USD 5.10 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 5.59% through 2030. The Global Acute Pancreatitis Market is a dynamic and evolving sector within the healthcare industry that encompasses the diagnosis, treatment, and management of acute pancreatitis, a severe inflammatory condition of the pancreas. This market has witnessed significant growth and transformation in recent years due to various factors, including changing lifestyle patterns, increasing alcohol consumption, and a rising incidence of obesity, all of which are contributing to the growing prevalence of acute pancreatitis worldwide. According to a November 2022 article by the NLM, acute pancreatitis is the most common gastrointestinal condition and the leading cause of hospitalization in the United States. Additionally, a July 2022 MedRxiv article reported that gallstone disease accounted for approximately 2.2 million ambulatory care visits, 1.1 million emergency department visits, and 615,000 hospital discharges. The same source noted that women are more likely to develop gallstones than men. One of the key drivers of this market is the increasing awareness and early diagnosis of acute pancreatitis, which has led to a surge in demand for diagnostic tests, such as imaging studies and blood tests, to accurately identify and assess the severity of the condition.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.10 Billion
Market Size 2030	USD 7.01 Billion
CAGR 2025-2030	5.59%
Fastest Growing Segment	Intravenous Fluids
Largest Market	North America

Key Market Drivers

Changing Lifestyle Patterns and Risk Factors

The global acute pancreatitis market is experiencing significant growth, in large part due to changing lifestyle patterns and the associated risk factors that are driving the increasing prevalence of this painful and potentially life-threatening condition. Modern lifestyles characterized by unhealthy dietary habits, high alcohol consumption, and a rising global obesity epidemic have created a perfect storm of risk factors that are contributing to the surge in acute pancreatitis cases worldwide. For instance, in December 2022, St. Jude Children's Research Hospital, in partnership with CalciMedica, Inc., initiated a Phase I/II clinical trial to evaluate the safety and effectiveness of CM4620 in children and young adults with asparaginase-induced acute pancreatitis. Also, in October 2022, Regeneron Pharmaceuticals initiated a Phase II clinical trial to assess the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia to prevent recurrent acute pancreatitis.

Key Market Challenges

High Treatment Costs

One of the primary drivers of high treatment costs for acute pancreatitis is the need for hospitalization. Severe cases of acute pancreatitis often require extended stays in the hospital, where patients receive specialized care, including pain management, nutritional support, and monitoring for complications. These extended hospital stays can result in exorbitant medical bills, particularly in countries with private healthcare systems. Early and accurate diagnosis of acute pancreatitis is critical for effective management. However, diagnostic tests, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and blood work, can be expensive. The cost of these diagnostic procedures can escalate the overall financial burden on patients and healthcare systems. In cases of severe acute pancreatitis, surgical interventions may be necessary to address complications like infected pancreatic necrosis or pseudocysts. Surgery, especially when performed laparoscopically or using minimally invasive techniques, can be costly and contribute significantly to the overall treatment expenses.

Key Market Trends

Advancements in Minimally Invasive Surgery

Advancements in minimally invasive surgical techniques have emerged as a pivotal trend in the global acute pancreatitis market, revolutionizing the treatment landscape for this severe pancreatic condition. Minimally invasive surgery (MIS), which includes procedures like laparoscopy and endoscopy, offers significant benefits such as reduced postoperative pain, shorter hospital stays, and faster patient recovery times. These advantages have not only improved patient outcomes but also contributed to the growth of the acute pancreatitis market in several ways.

One of the primary ways in which MIS is boosting the market is by enhancing patient comfort and overall satisfaction. Traditional open surgeries for acute pancreatitis often involve larger incisions and more extensive tissue disruption, leading to prolonged postoperative pain and recovery periods. In contrast, minimally invasive approaches involve smaller incisions, resulting in less pain, reduced scarring, and shorter hospitalization. This patient-centric focus has made MIS an attractive option for both patients and healthcare providers, driving its adoption and contributing to market growth.

Key Market Players

SCM Lifescience
GNT Pharma Co
Baxter International Inc.
B. Braun Melsungen AG
General Electric Company
Medtronic Plc
Boston Scientific Corporation
Fresenius Kabi USA
McNeil Consumer Healthcare
Sun BioPharma

Report Scope:

In this report, the Global Acute Pancreatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Pancreatitis Market, By Treatment:

Intravenous Fluid
Nutritional Support
Analgesics
Endoscopic Retrograde Cholangiopancreatography (ERCP)
Other treatments

Acute Pancreatitis Market, By Diagnosis:

Imaging tests
Laboratory Tests

Acute Pancreatitis Market, By End-User:

Hospitals & Clinics
Ambulatory care Centers
Others

Acute Pancreatitis Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Pancreatitis Market.

Available Customizations:

Global Acute Pancreatitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Global Acute Pancreatitis Market Outlook

4.1. Market Size & Forecast
- 4.1.1. By Value
4.2. Market Share & Forecast
- 4.2.1. By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Other treatments)
- 4.2.2. By Diagnosis (Imaging tests, Laboratory Tests)
- 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
- 4.2.4. By Region
- 4.2.5. By Company (2024)
4.3. Market Map
- 4.3.1. By Treatment
- 4.3.2. By Diagnosis
- 4.3.3. By End-User
- 4.3.4. By Region

5. Asia Pacific Acute Pancreatitis Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment
- 5.2.2. By Diagnosis
- 5.2.3. By End-User
- 5.2.4. By Country
5.3. Asia Pacific: Country Analysis
- 5.3.1. China Acute Pancreatitis Market Outlook
  - 5.3.1.1. Market Size & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share & Forecast
    - 5.3.1.2.1. By Treatment
    - 5.3.1.2.2. By Diagnosis
    - 5.3.1.2.3. By End-User
- 5.3.2. India Acute Pancreatitis Market Outlook
  - 5.3.2.1. Market Size & Forecast
    - 5.3.2.1.1. By Value
  - 5.3.2.2. Market Share & Forecast
    - 5.3.2.2.1. By Treatment
    - 5.3.2.2.2. By Diagnosis
    - 5.3.2.2.3. By End-User
- 5.3.3. Australia Acute Pancreatitis Market Outlook
  - 5.3.3.1. Market Size & Forecast
    - 5.3.3.1.1. By Value
  - 5.3.3.2. Market Share & Forecast
    - 5.3.3.2.1. By Treatment
    - 5.3.3.2.2. By Diagnosis
    - 5.3.3.2.3. By End-User
- 5.3.4. Japan Acute Pancreatitis Market Outlook
  - 5.3.4.1. Market Size & Forecast
    - 5.3.4.1.1. By Value
  - 5.3.4.2. Market Share & Forecast
    - 5.3.4.2.1. By Treatment
    - 5.3.4.2.2. By Diagnosis
    - 5.3.4.2.3. By End-User
- 5.3.5. South Korea Acute Pancreatitis Market Outlook
  - 5.3.5.1. Market Size & Forecast
    - 5.3.5.1.1. By Value
  - 5.3.5.2. Market Share & Forecast
    - 5.3.5.2.1. By Treatment
    - 5.3.5.2.2. By Diagnosis
    - 5.3.5.2.3. By End-User

6. Europe Acute Pancreatitis Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment
- 6.2.2. By Diagnosis
- 6.2.3. By End-User
- 6.2.4. By Country
6.3. Europe: Country Analysis
- 6.3.1. France Acute Pancreatitis Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment
    - 6.3.1.2.2. By Diagnosis
    - 6.3.1.2.3. By End-User
- 6.3.2. Germany Acute Pancreatitis Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment
    - 6.3.2.2.2. By Diagnosis
    - 6.3.2.2.3. By End-User
- 6.3.3. Spain Acute Pancreatitis Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment
    - 6.3.3.2.2. By Diagnosis
    - 6.3.3.2.3. By End-User
- 6.3.4. Italy Acute Pancreatitis Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Treatment
    - 6.3.4.2.2. By Diagnosis
    - 6.3.4.2.3. By End-User
- 6.3.5. United Kingdom Acute Pancreatitis Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Treatment
    - 6.3.5.2.2. By Diagnosis
    - 6.3.5.2.3. By End-User

7. North America Acute Pancreatitis Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment
- 7.2.2. By Diagnosis
- 7.2.3. By End-User
- 7.2.4. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Acute Pancreatitis Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment
    - 7.3.1.2.2. By Diagnosis
    - 7.3.1.2.3. By End-User
- 7.3.2. Mexico Acute Pancreatitis Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment
    - 7.3.2.2.2. By Diagnosis
    - 7.3.2.2.3. By End-User
- 7.3.3. Canada Acute Pancreatitis Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment
    - 7.3.3.2.2. By Diagnosis
    - 7.3.3.2.3. By End-User

8. South America Acute Pancreatitis Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment
- 8.2.2. By Diagnosis
- 8.2.3. By End-User
- 8.2.4. By Country
8.3. South America: Country Analysis
- 8.3.1. Brazil Acute Pancreatitis Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment
    - 8.3.1.2.2. By Diagnosis
    - 8.3.1.2.3. By End-User
- 8.3.2. Argentina Acute Pancreatitis Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment
    - 8.3.2.2.2. By Diagnosis
    - 8.3.2.2.3. By End-User
- 8.3.3. Colombia Acute Pancreatitis Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment
    - 8.3.3.2.2. By Diagnosis
    - 8.3.3.2.3. By End-User

9. Middle East and Africa Acute Pancreatitis Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment
- 9.2.2. By Diagnosis
- 9.2.3. By End-User
- 9.2.4. By Country
9.3. MEA: Country Analysis
- 9.3.1. South Africa Acute Pancreatitis Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment
    - 9.3.1.2.2. By Diagnosis
    - 9.3.1.2.3. By End-User
- 9.3.2. Saudi Arabia Acute Pancreatitis Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment
    - 9.3.2.2.2. By Diagnosis
    - 9.3.2.2.3. By End-User
- 9.3.3. UAE Acute Pancreatitis Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment
    - 9.3.3.2.2. By Diagnosis
    - 9.3.3.2.3. By End-User
- 9.3.4. Egypt Acute Pancreatitis Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Treatment
    - 9.3.4.2.2. By Diagnosis
    - 9.3.4.2.3. By End-User

10. Market Dynamics

10.1. Drivers
10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. Global Acute Pancreatitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. SCM Lifescience
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Current Capacity Analysis
- 14.1.5. Financials (In case of listed)
- 14.1.6. Recent Developments
- 14.1.7. SWOT Analysis
14.2. GNT Pharma Co
14.3. Baxter International Inc.
14.4. B. Braun Melsungen AG
14.5. General Electric Company
14.6. Medtronic Plc
14.7. Boston Scientific Corporation
14.8. Fresenius Kabi USA
14.9. McNeil Consumer Healthcare
14.10. Sun BioPharma